Hiroshi Ishiguro

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 5

Top Venues

Cancer medicine

Breast cancer research and treatment

Breast cancer (Tokyo, Japan)

This page only lists publications with an associated author ORCID identifier.

Publications

Kenichi Watanabe, Naoki Niikura, Yuichiro Kikawa, Mari Oba, Kokoro Kobayashi, Hiroshi Tada, Shinji Ozaki, Uhi Toh, Yutaka Yamamoto, Michiko Tsuneizumi, Toshitaka Okuno, Nobutaka Iwakuma, Takashi Takeshita, Takayuki Iwamoto, Hiroshi Ishiguro, Norikazu Masuda, Shigehira Saji
Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial). Breast cancer research and treatment (2023)
Hiroshi Ishiguro, Norikazu Masuda, Nobuaki Sato, Kenji Higaki, Takashi Morimoto, Yasuhiro Yanagita, Makiko Mizutani, Shoichiro Ohtani, Koji Kaneko, Tomomi Fujisawa, Masato Takahashi, Takayuki Kadoya, Nobuki Matsunami, Yutaka Yamamoto, Shinji Ohno, Toshimi Takano, Satoshi Morita, Sachiko Tanaka-Mizuno, Masakazu Toi
A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer. Breast cancer research and treatment 180 (3) (2020)
Moe Tsuda, Hiroshi Ishiguro, Naoko Toriguchi, Norikazu Masuda, Hiroko Bando, Masahiro Ohgami, Masato Homma, Satoshi Morita, Naohito Yamamoto, Katsumasa Kuroi, Yasuhiro Yanagita, Toshimi Takano, Satoru Shimizu, Masakazu Toi
Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial. Cancer medicine 9 (24) (2020)
Hiroshi Ishiguro, Shinji Ohno, Yutaka Yamamoto, Shintaro Takao, Nobuaki Sato, Tomomi Fujisawa, Takayuki Kadoya, Katsumasa Kuroi, Hiroko Bando, Yasufumi Teramura, Hiroji Iwata, Shiro Tanaka, Masakazu Toi
Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer. Breast cancer (Tokyo, Japan) 26 (5) (2019)
Hiroshi Ishiguro, Shigehira Saji, Shogo Nomura, Sunao Tanaka, Takayuki Ueno, Masahide Onoue, Hiroji Iwata, Takeharu Yamanaka, Yasutsuna Sasaki, Masakazu Toi
A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study). Cancer medicine 6 (12) (2017)

Hiroshi Ishiguro.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hiroshi Ishiguro